The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Cbeyond, Inc. (NASDAQ:CBEY) and other violations of state law by the board of directors of Cbeyond Inc. (NASDAQ:CBEY) relating to the proposed buyout of the Company by Birch Communications, Inc. (“Birch”). Cbeyond, Inc. (NASDAQ:CBEY) stock performance was 38.56% in last session and finished the day at $9.81. Traded volume was 12.17million shares in the last session and the average volume of the stock remained 222.13K shares. The beta of the stock remained 1.77. Cbeyond, Inc. (NASDAQ:CBEY) insider ownership is 4.70%.

Monday’s biggest gainer in the SV150 was Advanced Micro Devices Inc. (NYSE:AMD), with the Sunnyvale chipmaker roaring 11.7 percent higher to $4.12 in the first trading session since the company’s earnings report was released Thursday afternoon. Advanced Micro Devices, Inc. (NYSE:AMD) rose 11.65 percent to $4.12 Monday on volume of 102.65million shares. The intra-day range of the stock was $3.95 to $4.20. Advanced Micro Devices, Inc. (NYSE:AMD) has a market capitalization of $2.99billion.

Sarepta Therapeutics Inc (NASDAQ:SRPT) got some very good news this morning when the Food & Drug Administration reversed itself and agreed to consider Sarepta Therapeutics Inc (NASDAQ:SRPT)’s experimental drug for Duchenne muscular dystrophy for accelerated approval. Sarepta Therapeutics Inc (NASDAQ:SRPT)’s stock on Apr 21, 2014 reported a increase of 39.26% to the closing price of $33.98. Its fifty two weeks range is $12.12 -$55.61. The total market capitalization recorded $1.28billion. The overall volume in the last trading session was 13.11million shares. In its share capital, SRPT has 37.77million outstanding shares.

Merger and acquisition activity could provide a boost for sentiment in Europe on Tuesday with reports that Pfizer could launch another bid for fellow drug company AstraZeneca Plc (ADR) (NYSE:AZN). This comes after a reported £60 billion ($101 billion) takeover approach was rejected. Pfizer shares on the Dow Jones Industrial Average rose 2 percent on Monday in the U.S. AstraZeneca refused to comment on the speculation when contacted by CNBC. On Monday, shares of AstraZeneca plc (ADR) (NYSE:AZN) advanced 8.84% to close the day at $69.10. Company return on investment (ROI) is 9.00% and its monthly performance is recorded as 6.55%. AstraZeneca plc (ADR) (NYSE:AZN) quarterly revenue growth is 11.54%.